Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Acknowledgment of Commercial Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Seattle Genetics, Inc., and Servier Pharmaceuticals LLC.
2019 Year in Review™: Reflecting on Recent Evidence for the Treatment of Hematologic Malignancies
Release Date: May 28, 2020
Expiration Date: May 28, 2021
This Year in Review™ program covers exciting clinical trial efficacy and safety data reported in 2019 at major society meetings with the potential to impact your care of patients with hematologic malignancies. Three key thought leaders explore recent treatment advances and emerging agents in acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), lymphoma, acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), and CAR T-cell therapies. The faculty discuss how they are incorporating this information into their practice today and treatment adjustments they have made due to the coronavirus disease 2019 (COVID-19). This highly informative program provides expert guidance on these changing treatment paradigms to aid you in improving outcomes for your patients with hematologic malignancies.
Acknowledgement of Support
This activity is supported by educational grants from AstraZeneca Pharmaceuticals, Seattle Genetics, Inc., Servier Pharmaceuticals LLC.
Instructions for This Activity and Receiving Credit
You may immediately download your certificate.
This educational activity is directed toward medical oncologists and hematologists involved in the treatment and management of patients with hematologic malignancies. Fellows, nurse practitioners, nurses, physician assistants, pharmacists, researchers, and other health care professionals interested in the treatment of hematologic malignancies may also participate.
Upon successful completion of this educational activity, you should be better prepared to:
- Explain the study design, rationale, and results of recent clinical trials evaluating novel strategies for the treatment of hematologic malignancies
- Consider best practices to proactively mitigate and manage treatment-related adverse events in patients with hematologic malignancies
- Outline novel treatment options exploring CAR T-cell strategies across various hematologic malignancies
- Integrate novel therapeutic strategies into clinical practice to improve the treatment of patients with hematologic malignancies
Faculty, Staff, and Planners’ Disclosures
In accordance with ACCME Guidelines, PER® has identified and resolved all COI for faculty, staff, and planners prior to the start of this activity by using a multistep process.
Physician in Chief Hackensack Meridian Health Oncology Care Transformation Service
Chairman & Chief Physician Officer - John Theurer Cancer Center
Lydia Pfund Chair for Lymphoma
Academic Chairman Oncology- Hackensack Meridian School of Medicine at Seton Hall University
Professor of Medicine – Georgetown University
Disclosures: Grant/Research Support: Acerta Pharma, Celgene, Constellation Pharmaceuticals, Hackensack University Medical Center, F. Hoffmann-La Roche, Infinity Pharmaceuticals, Janssen Pharmaceuticals, Karyopharm Therapeutics, Kite Pharma/Gilead Sciences; Consultant: Acerta Pharma, Celgene, Physicians’ Education Resource®, LLC; Xcenda; Stock/Shareholder: COTA; Other Support: Physicians’ Education Resource®, LLC (travel expenses).
Associate Director for Clinical Sciences
Chao Family Comprehensive Cancer Center
Sue and Ralph Stern Center for Cancer Clinical Trials and Research
Professor of Medicine, Division of Hematology/Oncology
Department of Medicine
University of California
Disclosures: Grant/Research Support: AstraZeneca, Genentech (Member of Roche Group), Pharmacyclics.
Professor of Medicine
Director, Clinical and Translational Leukemia Program
Weill Medical College of Cornell University
The NewYork-Presbyterian Hospital
New York, NY
Disclosures: Consultancy or Advisory Board or Data and Safety Monitoring Committee: AbbVie, Actinium Pharmaceuticals, Agios Pharmaceuticals, Amphivena Therapeutics, Argenx, Array BioPharma, Astellas Pharma, Astex Pharmaceuticals, Bayer, Celgene, Celltrion, Daiichi Sankyo, Eisai, Epizyme, Helsinn, Janssen, Jazz Pharmaceuticals, MEI Pharma (independent data monitoring committee chair), Novartis, Orsenix, Otsuka Pharmaceutical, Pfizer, Roche/Genentech, Sandoz, Takeda (independent review committee chair), Trovagene; Research Support: Cellectis.
The staff Physicians' Education Resource®, LLC (PER®) have no relevant financial relationships with commercial interests to disclose.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a healthcare professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER® or any company that provided commercial support for this activity.
Login or Register to Start Activity
Please use the form below to Register or Log In to begin Activity.